SLC16A13 is a lactate transporter expressed at the plasma membrane and a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (Schumann et al., 2021), while its role in tumor needs to be further explored. The gene discussed is SLC16A13; the disease is metabolic dysfunction-associated steatotic liver disease.